SG Americas Securities LLC Raises Position in Eagle Pharmaceuticals, Inc. (EGRX)

SG Americas Securities LLC increased its holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 60.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,511 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,706 shares during the quarter. SG Americas Securities LLC’s holdings in Eagle Pharmaceuticals were worth $269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Kopp Investment Advisors LLC grew its position in Eagle Pharmaceuticals by 0.3% during the 2nd quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 10 shares during the last quarter. Alps Advisors Inc. grew its position in Eagle Pharmaceuticals by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,985 shares of the specialty pharmaceutical company’s stock valued at $472,000 after purchasing an additional 16 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Eagle Pharmaceuticals by 0.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,269 shares of the specialty pharmaceutical company’s stock valued at $889,000 after purchasing an additional 82 shares during the last quarter. D.A. Davidson & CO. grew its position in Eagle Pharmaceuticals by 2.4% during the 2nd quarter. D.A. Davidson & CO. now owns 4,350 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 100 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its position in Eagle Pharmaceuticals by 6.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 120 shares during the last quarter.

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) opened at $56.11 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. The stock has a market cap of $822.48, a PE ratio of 9.05 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a 1-year low of $45.05 and a 1-year high of $97.15.

Several analysts recently commented on the stock. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. Mizuho reissued a “sell” rating and set a $37.00 price objective on shares of Eagle Pharmaceuticals in a research report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $75.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Finally, ValuEngine raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $62.33.

TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Raises Position in Eagle Pharmaceuticals, Inc. (EGRX)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/20/sg-americas-securities-llc-raises-position-in-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit